Fewer than 4 Weeks Left to Participate in ARNA Genomics ICO

Share Article

What If We Never Had to Treat Stage 3 Cancer Again?

Can you imagine a world in which we never have to treat stage 3 breast cancer?

NEWTON, Mass. (PRWEB)January 23, 2018

ARNA Genomics, an innovative Precision Medicine and Blockchain technology company, today announced that it has passed the Soft Cap threshold by raising over $1M amid an Initial Coin Offering (ICO) from over 200 investors spanning nations such as the United States, Canada, Germany, France, China, Japan, Australia, among others.

ARNA Genomics, currently based in Russia, aims to use the funding, still ongoing through February 10, 2018, toward moving its breast cancer testing and diagnostic services to the US.

Leveraging Blockchain technology in its proprietary suite of Liquid Biopsy tests, ARNA has set out to bring the benefits of Precision Medicine to everyone with its affordable breast cancer test which helps diagnose the disease earlier, better, and cheaper -- while accelerating trust in collaborative biomedical research -- leading to more positive prognosis for patients and reducing disease burden for all.

Started by 5 lifelong friends with a track record of science, innovation, and entrepreneurship, ARNA’s founding team is excited to prepare for the rigors of FDA trials and approvals. The team includes:

Investors and the public at large who are interested in learning more about the ICO, and the potential to participate in this round, should note the deadline for issuing ARNA Tokens ends on February 10, 2018. https://token.arnagenomics.com

About ARNA Genomics

Based in Moscow, Russia, ARNA Genomics is an innovative Precision Medicine and Blockchain technology company specializing in the development of blood tests for early diagnosis of cancer and monitoring the efficacy of cancer treatment tied to ARNA Panacea, a Blockchain Proof-Of-Research protocol designed to accelerate and lower the cost of consumer access to trusted, collaborative Precision Medicine worldwide.